Drug Development

Clinical Trials Market Trends Alzheimer's Treatment Market Competition Weight Loss Drugs Oncology FDA Approvals Non-invasive Techniques Antidepressants Cost Analysis FDA Approval New Products Clinical Therapies Obesity Drugs Personalized Medicine Larger-Molecule Drugs AI in Drug Discovery Phase 3 Clinical Trials Pediatric Medication Biosimilars Clinical Studies Research and Development Cellular Biology Pipeline Expansion Weight-loss Drugs Oral Medications Drug Screening Combination Therapies

Sanofi to Acquire Blueprint Medicines for $9.1 Billion, Boosting Its Rare Immunology Pipeline

The Q3 closing will add Blueprint’s FDA-approved systemic mastocytosis therapy Ayvakit alongside late-stage candidates to Sanofi’s portfolio.

Experimental ALS Drug Shows Unprecedented Effects in Rare Genetic Cases

U.S. Drug Launch Prices Skyrocket, Driven by Rare Disease Treatments

AbbVie Raises 2025 Profit Forecast Following Strong Q1 Growth in Immunology Drugs

Latent Labs Secures $50M to Revolutionize Protein Design with AI

AbbVie Reports Strong Sales Growth for Skyrizi and Rinvoq, Boosts 2027 Revenue Outlook

Bristol Myers Squibb Surges on Strong Q2 Performance and Raised Guidance

Johns Hopkins Engineers Synthetic Cell for Targeted Drug Delivery

28 Healthcare Providers Join Biden's AI Safety Commitments